Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyLee A Honigberg, Ashley M Smith, Mint Sirisawad, et al.
Arthritis Research & Therapy|November 10, 2012
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupusJack Hutcheson, Kamala Vanarsa, Anna Bashmakov, et al.
British Journal of Anaesthesia|June 25, 2018
Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomesD J Buggy, J Freeman, M Z Johnson, et al.
Lancet (London, England)|October 25, 2019
Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trialDaniel I Sessler, Lijian Pei, Yuguang Huang, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Leukemia|April 27, 2013
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyS E M Herman, X Sun, E M McAuley, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Molecular Cancer Therapeutics|August 8, 2006
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivoZ Alexander Cao, Kathryn E Bass, Sriram Balasubramanian, et al.
Npj Drug Discovery|July 1, 2026
Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunityLih-Yun Hsu, James T Rosenbaum, Erik Verner, et al.
Pageof 21